乳腺卵巢双原发癌(double primary breast and ovarian cancer,DPBOC)为女性生殖系统多原发恶性肿瘤(multiple primary malignant neoplasms,MPMNs)常见的一种类型。乳腺、卵巢均为性激素调节器官,两者有着相似的内分泌调节机制。由于...乳腺卵巢双原发癌(double primary breast and ovarian cancer,DPBOC)为女性生殖系统多原发恶性肿瘤(multiple primary malignant neoplasms,MPMNs)常见的一种类型。乳腺、卵巢均为性激素调节器官,两者有着相似的内分泌调节机制。由于乳腺癌患者确诊时多为早期,预后佳,再患原发性卵巢癌的风险较普通女性增高。对散发性乳腺癌或卵巢癌的研究已相对成熟,而DPBOC的发病机制尚不明确,且由于缺乏敏感度及特异度较高的筛查手段,其难以与转移性肿瘤相鉴别,因此较少引起临床医师的关注。综述DPBOC的发病机制、与乳腺癌卵巢转移的鉴别诊断、治疗及预防等,对此类疾病进行深入探讨,使临床医师重视第二原发癌器官的早期监测,对高危人群采取必要的预防措施,抓住最佳治疗时机,尽可能延长双原发癌患者的生存时间。展开更多
Objective: To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction(JBJD) in patients with metastatic colorectal cancer(mCRC) who have failed second or above lines ...Objective: To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction(JBJD) in patients with metastatic colorectal cancer(mCRC) who have failed second or above lines treatment, in order to provide more treatment option for mCRC patients by integrated medicine. Methods: Thirteen patients were selected from a single-arm, open-label clinical study from April 2019 to September 2020. The patients were treated with low-dose apatinib(250 mg, once a day) and S-1(20 mg, twice a day) combined with JBJD for at least one cycle and were followed up to August 2021. The primary endpoint was disease progression-free survival(PFS). Disease control rate(DCR), objective response rate(ORR), and overall survival(OS) of patients were observed as the secondary endpoints. Adverse events were recorded as well. Results: The average age of the 13 patients was 56.5±13.0 years and 76.9% were male. The median PFS and median OS were 4.6 and 8.3 months, respectively. The ORR was 7.7%(1/13) while the DCR was 61.5%(8/13). The common adverse events were hypertension, proteinuria, elevated transaminase, and thrombocytopenia. One patient experienced thrombocytopenia of grade 3. Conclusions: Patients with mCRC after failure of the second or above lines of treatment may potentially benefit from the treatment of low-dose apatinib and S-1 combined with JBJD because of its similar effect as the standard dose of target therapy and relatively better safety.(Registration No. ChiCTR1900022673)展开更多
文摘乳腺卵巢双原发癌(double primary breast and ovarian cancer,DPBOC)为女性生殖系统多原发恶性肿瘤(multiple primary malignant neoplasms,MPMNs)常见的一种类型。乳腺、卵巢均为性激素调节器官,两者有着相似的内分泌调节机制。由于乳腺癌患者确诊时多为早期,预后佳,再患原发性卵巢癌的风险较普通女性增高。对散发性乳腺癌或卵巢癌的研究已相对成熟,而DPBOC的发病机制尚不明确,且由于缺乏敏感度及特异度较高的筛查手段,其难以与转移性肿瘤相鉴别,因此较少引起临床医师的关注。综述DPBOC的发病机制、与乳腺癌卵巢转移的鉴别诊断、治疗及预防等,对此类疾病进行深入探讨,使临床医师重视第二原发癌器官的早期监测,对高危人群采取必要的预防措施,抓住最佳治疗时机,尽可能延长双原发癌患者的生存时间。
基金Supported by National Administration of Traditional Chinese Medicine:Qihuang Scholar (No.02045004)Collaborative Pilot Project of Clinical Traditional Chinese and Western Medicine for Major and Difficult Diseases in 2019 (No.070030003)。
文摘Objective: To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction(JBJD) in patients with metastatic colorectal cancer(mCRC) who have failed second or above lines treatment, in order to provide more treatment option for mCRC patients by integrated medicine. Methods: Thirteen patients were selected from a single-arm, open-label clinical study from April 2019 to September 2020. The patients were treated with low-dose apatinib(250 mg, once a day) and S-1(20 mg, twice a day) combined with JBJD for at least one cycle and were followed up to August 2021. The primary endpoint was disease progression-free survival(PFS). Disease control rate(DCR), objective response rate(ORR), and overall survival(OS) of patients were observed as the secondary endpoints. Adverse events were recorded as well. Results: The average age of the 13 patients was 56.5±13.0 years and 76.9% were male. The median PFS and median OS were 4.6 and 8.3 months, respectively. The ORR was 7.7%(1/13) while the DCR was 61.5%(8/13). The common adverse events were hypertension, proteinuria, elevated transaminase, and thrombocytopenia. One patient experienced thrombocytopenia of grade 3. Conclusions: Patients with mCRC after failure of the second or above lines of treatment may potentially benefit from the treatment of low-dose apatinib and S-1 combined with JBJD because of its similar effect as the standard dose of target therapy and relatively better safety.(Registration No. ChiCTR1900022673)
